8.895
price down icon0.73%   -0.065
after-market Dopo l'orario di chiusura: 8.75 -0.145 -1.63%
loading
Precedente Chiudi:
$8.96
Aprire:
$8.95
Volume 24 ore:
113.03K
Relative Volume:
0.18
Capitalizzazione di mercato:
$20.54M
Reddito:
$1.47M
Utile/perdita netta:
$-97.61M
Rapporto P/E:
-5.9698
EPS:
-1.49
Flusso di cassa netto:
$-80.90M
1 W Prestazione:
-30.83%
1M Prestazione:
+80.43%
6M Prestazione:
-13.81%
1 anno Prestazione:
-40.08%
Intervallo 1D:
Value
$8.5019
$9.28
Intervallo di 1 settimana:
Value
$8.35
$14.88
Portata 52W:
Value
$3.8101
$37.50

Lyra Therapeutics Inc Stock (LYRA) Company Profile

Name
Nome
Lyra Therapeutics Inc
Name
Telefono
617-373-4600
Name
Indirizzo
480 ARSENAL WAY, WATERTOWN, MA
Name
Dipendente
30
Name
Cinguettio
@LyraTx
Name
Prossima data di guadagno
2025-03-12
Name
Ultimi documenti SEC
Name
LYRA's Discussions on Twitter

Confronta LYRA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
LYRA
Lyra Therapeutics Inc
8.895 20.54M 1.47M -97.61M -80.90M -1.49
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-05-07 Downgrade BofA Securities Buy → Underperform
2024-05-07 Downgrade H.C. Wainwright Buy → Neutral
2024-05-07 Downgrade Jefferies Buy → Hold
2024-05-06 Downgrade William Blair Outperform → Mkt Perform
2023-10-06 Ripresa BTIG Research Buy
2023-08-31 Iniziato H.C. Wainwright Buy
2022-05-24 Iniziato Cantor Fitzgerald Overweight
2020-05-26 Iniziato BTIG Research Buy
2020-05-26 Iniziato BofA/Merrill Buy
2020-05-26 Iniziato Jefferies Buy
2020-05-26 Iniziato William Blair Outperform
Mostra tutto

Lyra Therapeutics Inc Borsa (LYRA) Ultime notizie

pulisher
Jun 16, 2025

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha

Jun 16, 2025
pulisher
Jun 14, 2025

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Stake Lessened by Two Sigma Investments LP - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why - sharewise

Jun 12, 2025
pulisher
Jun 10, 2025

H.C. Wainwright lifts Lyra Therapeutics stock target to $16 By Investing.com - Investing.com Canada

Jun 10, 2025
pulisher
Jun 10, 2025

Lyra Therapeutics (LYRA) Price Target Raised by HC Wainwright & Co. | LYRA Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

H.C. Wainwright Ups Target Price for Lyra Therapeutics (LYRA) to $16 | LYRA Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 09, 2025

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Sold by Two Sigma Advisers LP - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win - insights.citeline.com

Jun 06, 2025
pulisher
Jun 05, 2025

Northern Trust Corp Has $59,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Study: LYR-210 Shows Promise in Chronic Rhinosinusitis With Nasal Polyps - Pharmacy Times

Jun 04, 2025
pulisher
Jun 04, 2025

BNP Paribas Financial Markets Makes New Investment in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Best Biotech Stocks To Watch Now – June 2nd - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Biotech Triumphs: Lyra, Vera, And US Gold Shine Bright - Finimize

Jun 03, 2025
pulisher
Jun 03, 2025

Lyra Therapeutics stock hits 52-week high at $28.66 By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled - Asianet Newsable

Jun 03, 2025
pulisher
Jun 03, 2025

Lyra Therapeutics reports positive phase 3 trial results for CRS treatment By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

Applied Digital Corp, Meta Platforms, Alphabet, Lyra Therapeutics, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled By Stocktwits - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

Redemption for Lyra as second phase III rhinosinusitis trial hits goal - BioWorld MedTech

Jun 02, 2025
pulisher
Jun 02, 2025

One year after massive layoffs, Lyra stock soars 400% on trial win - The Business Journals

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics (LYRA) Surges 376% on Positive Phase 3 Trial R - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics (LYRA) Surges 376% on Positive Phase 3 Trial Results - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Microcap Lyra Therapeutics surges 376% on phase 3 rhinosinusitis data - Seeking Alpha

Jun 02, 2025
pulisher
Jun 02, 2025

Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win - Yahoo Finance

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Spikes 417% as LYR-210 Redefines CRS Therapy - Wall Street Pit

Jun 02, 2025
pulisher
Jun 02, 2025

LYR-210 Nasal Implant for CRS Brings Symptom Relief in Phase 3 ENLIGHTEN 2 - HCPLive

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics says ENLIGHTEN 2 trial of LYR-210 met primary endpoint - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Soars on Breakthrough Nasal Implant Results - RagingBull

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Shares Soar 603.25% to $34.67 on LYR-210 Trial Success - Trading Pedia

Jun 02, 2025
pulisher
Jun 02, 2025

Transcript : Lyra Therapeutics, Inc.Special Call - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics stock hits 52-week high at $28.66 - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

This penny stock just spiked 550% in a day; Time to buy? - Finbold

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Stock (LYRA) Rockets 530% on Phase 3 Trial Results - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210 - MarketScreener

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Announces Positive Phase 3 Trial Results - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

LYRA Sees Promising Results in ENLIGHTEN 2 Phase 3 Trial for CRS Treatment | LYRA Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics reports positive phase 3 trial results for CRS treatment - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics stock soars on positive Phase 3 trial results By Investing.com - Investing.com Canada

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics stock soars on positive Phase 3 trial results - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewswire

Jun 02, 2025
pulisher
Jun 01, 2025

Lyra Therapeutics (NASDAQ:LYRA) Stock Rating Upgraded by Wall Street Zen - Defense World

Jun 01, 2025

Lyra Therapeutics Inc Azioni (LYRA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):